OrganOx Phase 2 Clinical Investigation

OrganOx 2 期临床研究

• 批准号: 101454
• 金额: $ 297.39万
• 依托单位: ORGANOX LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101454
• 关键词: OrganOx; Phase; Clinical; Investigation

OrganOx® Ltd. is a company focussed on increasing the quality & supply of organs for transplantation. It’s first product, the OrganOx metra™, a patented liver preservation device, entered a phase I clinical study in Sept 2012 at Kings College Hospital, London. The metra will revolutionise liver transplantation globally by enabling objective assessment of liver viability, planned as opposed to emergency procedures, but most importantly by greatly increasing the supply of livers for transplantation. This project will part fund a phase II clinical study in the US to enable an application to the FDA for marketing authorisation. Export of the metra to the US will double the market opportunity thereby delivering increased revenues back to the UK building product pipeline & additional UK job opportunities together with the ability to save thousands of extra lives each year.

OrganOx®Ltd.是一家专注于提高移植器官质量和供应的公司。它的第一个产品OrganOx Metra™是一种获得专利的肝脏保存设备，于2012年9月在伦敦国王学院医院进入I期临床研究。Metra将在全球范围内为肝脏移植带来革命性的变化，因为它能够对肝脏的生存能力进行客观的评估，而不是按计划进行，而不是紧急手术，但最重要的是通过大幅增加供移植的肝脏供应。该项目将部分资助在美国的第二阶段临床研究，以使向FDA申请上市授权成为可能。向美国出口Metra将使市场机会加倍，从而为英国建筑产品管道带来更多收入&增加英国的就业机会，并有能力每年挽救数千人的生命。